
The Coeliac Disease Assessment Questionnaire (CDAQ): comparison of the paper and electronic versions

> Michele Peters, Helen Crocker, Crispin Jenkinson Nuffield Department of Population Health





# Aims

Coeliac disease is an auto-immune disorder affecting approximately 1% of the population. Currently the only treatment is a life long gluten-free diet, although research is underway to develop pharmacological treatments.

The Coeliac Disease Assessment Questionnaire (CDAQ) was developed as a paper version and includes five dimensions (stigma, social isolation, symptoms, dietary burden, and worries and concerns). Dimension scores and an overall summary

## **Table 3.** Significant differences in CDAQ dimension scores by mode of administration

	<b>Paper</b> Mean (SD)	<b>Electronic</b> Mean (SD)	р
Stigma	54.4 (22.7)	48.5 (20.1)	0.013
Social isolation	66.2 (23.7)	60.4 (24.0)	0.027

45

40

35

25

score can be calculated. Electronic surveys are increasingly used in health research, and present some advantages over paper-based surveys such as reduced cost and ease of analysis (McPeake et al 2014). The aims were to develop and test an electronic version of the CDAQ, and to compare the findings to the postal version of the CDAQ.

### **Methods**

The CDAQ was administered to 1443 members of Coeliac UK, either by a postal survey (n=500) or as an electronic online version (n=943) using Qualtrics Software. Respondents were asked to complete the CDAQ and some demographics and disease-related questions (e.g. time since diagnosis, dietary adherence).

Data were analysed in SPSS version 20. Data analysis aimed to compare the electronic and paper-based versions, using Chi<sup>2</sup> for univariate analysis and regression analysis for multi-variate analysis. Only significant results are reported.

#### Results

An overall response rate of 24.9% (n=359) was achieved, with considerable differences between the electronic and paper versions (Table 1). Of those receiving the questionnaire electronically, 63.6% (n=600) opened the email, and 19.8% (n=187) of these clicked through to the survey. The majority (73.3%) of those clicking through to the online survey completed the questionnaire.


## Conclusion

The electronic version of the CDAQ seems less acceptable to people with coeliac disease as indicated by the substantially lower response rate. However, this is not unique to the CDAQ with evidence showing lower response rates for electronic versus paper-based questionnaires in different studies (Nulty, 2008).

Differences in scores for individual items and two dimensions were found according to mode of administration. Further differences in scores were found for gender. Previous research (e.g. Norstrom et al 2011) suggests that women with coeliac disease report lower quality of life than men. Hence, it is likely that differences between modes of administration were related to the higher proportion of women responding to the electronic version rather than true differences in the electronic and paper-based versions of the CDAQ. Further research into the acceptability of the electronic CDAQ is underway.

### **Graph 1.** Responses (%) to CDAQ items by mode of administration

(paper and electronic )



Respondents to the electronic version were more likely to be female (72.1% vs 52.0%, p<0.001) and to be working (full-time, part-time and self-employed) (p=0.02)

 Table 1: Response rate by mode of administration


Mode	Surveys sent	Surveys returned
Paper	500	223 (44.6%)
Electronic	943	137 (14.5%)
Total	1443	360 (24.9%)

**Table 2:** Internal consistency (Cronbach's alpha) by mode of administration


Dimension	Paper	Electronic
Stigma	0.89	0.87
Dietary burden	0.84	0.86
Symptoms	0.81	0.84
Social isolation	0.87	0.89
Worries and concerns	0.81	0.83

Licensing


- Internal consistency was good regardless of mode of administration (Table 2)
- Significant differences were  $\bullet$ found for five items (Graph 1) two dimensions for and (stigma and social isolation) (Table 3
- Female participants reported significantly worse scores on 26 of the 32 individual CDAQ items, the five dimensions scores and the overall CDAQ significant The score. mode difference for of administration did not remain for stigma and social isolation when controlling for gender.




7. ... have you felt worried that a family member may have or could develop coeliac disease? (p=0.002)



23. ...have you felt you were a nuisance to other people? (p=0.044)



16. ...have you felt isolated from others because of your coeliac disease? (p=0.03)



#### References

Nulty DD (2008). The adequacy of response rates to online and paper surveys: what can be done? Assessment & Evaluation in Higher Education 33; 3:301-314

Norstrom F, Lindholm L, Sandstrom O, Nordyke K and Ivarsson A (2011). Delay to celiac disease diagnosis and its implications for health-related quality of life. BMC Gastroenterology 11: 118.

McPeak J, Bateson M, O'Neill A (2014). Electronic Surveys: how to maximise success. Nurse Researcher 21; 3:24-26

Rarely Sometimes Often Never Always



#### **Acknowledgements and funding**

We would like to thank Coeliac UK for their recruitment support and the respondents for taking part in the study. The study was funded by Coeliac UK. Michele Peters is a senior researcher of the Department of Health funded Policy Research Unit on Quality and Outcomes of Person-centred care (QORU), a collaboration between the London School of Economics and Political Science (LSE) and the Universities of Kent and Oxford.



The CDAQ is managed as part of a wide Patient Reported Outcome portfolio by Clinical Outcomes at Oxford University Innovation, the University of Oxford's technology transfer company. To use the CDAQ, please complete a Licence Request Form here: <u>http://process.innovation.ox.ac.uk/</u>.

Please go to http://innovation.ox.ac.uk/clinical-outcomes/ for any further information regarding the CDAQ and its development, sample copies, a list of available languages and example studies. For further information please contact: <u>healthoutcomes@innovation.ox.ac.uk</u>